The byproducts of intestinal bacteria that decompose the tryptophan can restore the hormone secretary intestinal cells that obesity reduces. This is a natural alternative and without side effects to GLP-1 medicines, such as Ozempic.
O tryptophan It is an essential amino acid that our body cannot produce. It is obtained through food, it plays a crucial role in protein production and is a precursor of several important molecules.
It made a list like 12 foods rich in tryptophan, starting with the richest: cheese; peanut; Cashews; Chicken meat; egg; pea; High; almond; avocado; cauliflower; potato; banana.
In the process of decomposition of tryptophan, the specialized intestinal cells, called entire cells (CEE)segregate important hormones, such as the peptide 1 similar to the glucagon (GLP-1)which help regulate insulin production and appetite.
This is the famous GLP-1 that medicines like the Ozepic and Wegovy imitate.
A study recently in International Journal of Molecular Sciences It revealed that obesity significantly reduces the number of CEES, leading to a metabolic dysfunction. However, the by -products produced by intestinal bacteria, when they decompose certain amino acids, can restore them.
“Our findings suggest that microbial metabolites derived from the dietary tryptophan may reverse the reductions associated with obesity in hormone secretory cells,” he told, to, Alip borthakurPhD, Marshall University and senior author of the study.
“This points to a Potential therapeutic strategy that takes advantage of intestinal microbes to improve metabolic results in obesity“He stressed.
The “ozempic” that nature has given us
The results of the new study suggest a non -drug strategy for restore LPG-1 production in obesityencouraging the growth of tryptophan metabolizing intestinal bacteria (for example, probiotics such as L. acidophilus) and using tripytophan -rich dietary supplements to feed these bacteria.
Unlike GLP-1 synthetic medications, which can cause side effects such as nausea, this approach can naturally stimulate the production of LPG-1 by the body itself, with less risks.
The study also highlights the potential of personalized nutrition and microbiome therapies, where adapted diets or supplements are used to increase microbial production of beneficial metabolites to prevent or treat metabolic obesity and dysfunction, such as type 2 diabetes, which often accompanies the disease.
